The global CRO preclinical market is projected to reach USD 7.8 billion by 2027, up from an estimated USD 6.8 billion in 2017. According to a report b...
- http://www.prisysbiotech.com/ The detection and management of diseases such as cancer, diabetes and other metabolic disorders remains an ongoing challenge for scientists and manufacturers alike. This field of medical science is continuously transforming and researchers are introducing new agents to fight disease and improve patient care. It is vital that such findings are shared in order to enable future clinical trials to find their target populations. For this purpose, medical ethics committees are making clinical trials mandatory for licensing purposes. Through such policies, both small and large pharmaceutical companies are compelled to submit their drugs for clinical trials before their commercial release.
- http://www.prisysbiotech.com/ The detection and management of diseases such as cancer, diabetes and other metabolic disorders remains an ongoing challenge for scientists and manufacturers alike. This fie...See more
A Shanghai-based integrated Nonhuman Primate CRO and research platform providing disease models on key disease areas for drug efficacy or pharmacology assessment in nonclinical or preclinical phase, with human translatable endpoints.